Moreover, we showed that the antihelminthic drug niclosamide inhibits S100A4 transcription and we are currently performing a clinical phase II trial on stage IV CRC, in which niclosamide is applied in terms of a drug repositioning approach (EudraCT 2014‐005151‐20, NCT02519582). Here, S100A4 is linked to colorectal carcinoma.